Keros Therapeutics, Inc.
KROS
$11.34
$0.312.81%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 385.00K | 14.26M | 18.17M | 211.25M | 3.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 385.00K | 14.26M | 18.17M | 211.25M | 3.04M |
| Cost of Revenue | 17.81M | 19.52M | 43.50M | 48.71M | 45.63M |
| Gross Profit | -17.43M | -5.26M | -25.34M | 162.54M | -42.59M |
| SG&A Expenses | 11.74M | 10.13M | 14.48M | 10.50M | 10.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.56M | 29.65M | 57.99M | 59.21M | 56.30M |
| Operating Income | -29.17M | -15.38M | -39.82M | 152.04M | -53.25M |
| Income Before Tax | -24.98M | -8.70M | -32.92M | 158.49M | -45.73M |
| Income Tax Expenses | -1.51M | -1.42M | -2.22M | 10.04M | 300.00K |
| Earnings from Continuing Operations | -23.46M | -7.28M | -30.70M | 148.45M | -46.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.46M | -7.28M | -30.70M | 148.45M | -46.03M |
| EBIT | -29.17M | -15.38M | -39.82M | 152.04M | -53.25M |
| EBITDA | -28.77M | -14.99M | -39.45M | 152.38M | -52.92M |
| EPS Basic | -0.86 | -0.18 | -0.76 | 3.66 | -1.14 |
| Normalized Basic EPS | -0.57 | -0.13 | -0.51 | 2.44 | -0.71 |
| EPS Diluted | -0.86 | -0.18 | -0.76 | 3.62 | -1.14 |
| Normalized Diluted EPS | -0.57 | -0.13 | -0.51 | 2.41 | -0.71 |
| Average Basic Shares Outstanding | 27.20M | 40.62M | 40.61M | 40.56M | 40.34M |
| Average Diluted Shares Outstanding | 27.20M | 40.62M | 40.61M | 41.02M | 40.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |